Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma
Open Access
- 15 May 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3565-3571
Abstract
Grace Baek, Gaurav Varma, Samuel Yamshon, Herman J van Besien, Nancy L. Bartlett, Marcus P. Watkins, Harsh R. Shah, Kelsey Baron, Reid W Merryman, Ayo SamuKeywords
This publication has 23 references indexed in Scilit:
- Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centersBlood Cancer Journal, 2025
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s LymphomaNew England Journal of Medicine, 2024
- Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2024
- Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin LymphomaJAMA Oncology, 2023
- A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphomaAnnals of Hematology, 2023
- Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphomaAmerican Journal of Hematology, 2023
- Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyThe Lancet Haematology, 2021
- Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trialThe Lancet Haematology, 2020
- Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trialThe Lancet Oncology, 2017
- Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804Annals of Oncology, 2007